Zai LabZLAB
ZLAB
About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Employees: 2,175
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
54% more capital invested
Capital invested by funds: $712M [Q2] → $1.09B (+$381M) [Q3]
13% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 32
0.42% more ownership
Funds ownership: 4.13% [Q2] → 4.55% (+0.42%) [Q3]
0% more funds holding
Funds holding: 102 [Q2] → 102 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
68% less call options, than puts
Call options by funds: $5.46M | Put options by funds: $17.2M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$44
65%
upside
Avg. target
$44
65%
upside
High target
$44
65%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama 27% 1-year accuracy 16 / 60 met price target | 65%upside $44 | Overweight Maintained | 21 Oct 2024 |
Financial journalist opinion
Based on 4 articles about ZLAB published over the past 30 days
Neutral
Business Wire
1 week ago
Zai Lab Announces Participation in Investor Conference in January 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2025: 43rd Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-present.
Neutral
Business Wire
2 weeks ago
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally adv.
Neutral
Business Wire
3 weeks ago
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC); NUZYRA® (omadacycline) is ren.
Neutral
Business Wire
4 weeks ago
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization inf.
Neutral
Business Wire
1 month ago
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the anticipated closing of its previously announced underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. In addition, Zai Lab today announced that the underwriters in the offering fully exercis.
Neutral
Business Wire
1 month ago
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,843,137 American depositary shares (“ADSs”), each representing ten ordinary shares of the Company, at a price of US$25.50 per ADS. The gross proceeds to Zai Lab from the offering, before deducting underwriting discounts and commissions and other offeri.
Neutral
Business Wire
1 month ago
Zai Lab Announces Proposed Public Offering of American Depositary Shares
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $200.0 million of American depositary shares (“ADSs”), each representing ten ordinary shares of the Company with a par value of $0.000006 per share. All ADSs will be offered by Zai Lab. Zai Lab expects to grant the underwriters a 30-day option to p.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neutral
Seeking Alpha
1 month ago
Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado – President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Operator Hello, ladies and gentlemen. Thank you for standing by.
Neutral
Business Wire
1 month ago
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate updates. “In the third quarter, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The launch of VYVGART® has been a.
Charts implemented using Lightweight Charts™